Quick Answer
VOLITIONRX LTD reported Operating Income Loss of -$21.74 million for the year ending 2025.
- VOLITIONRX LTD showed an increase of +19.6% in Operating Income Loss from 2024 to 2025.
- This data is from VOLITIONRX LTD's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), VOLITIONRX LTD's Operating Income Loss has declined by 733.4%.
- Historical annual values: Fiscal year 2025: -$21.74 million | Fiscal year 2024: -$27.02 million | Fiscal year 2023: -$35.99 million | Fiscal year 2022: -$31.78 million | Fiscal year 2021: -$28.33 million | Fiscal year 2020: -$21.25 million | Fiscal year 2019: -$16.04 million | Fiscal year 2018: -$17.90 million | Fiscal year 2017: -$14.70 million | Fiscal year 2016: -$12.43 million | Fiscal year 2015: -$10.01 million | Fiscal year 2014: -$5.95 million | Fiscal year 2013: -$4.58 million | Fiscal year 2012: -$4.08 million | Fiscal year 2011: -$2.61 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: